Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Privosegtor (Primary) ; Corticosteroid
  • Indications Optic neuritis
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ACUITY
  • Sponsors Accure Therapeutics; Oculis Pharma

Most Recent Events

  • 31 Mar 2026 According to an Oculis Pharma media release, Privosegtor has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of optic neuritis (ON), a rare, sight-threatening condition that is often a relapse of multiple sclerosis or its first clinical manifestation, based results from this trial.
  • 16 Mar 2026 According to an Oculis Pharma media release, company announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting.
  • 06 Jan 2026 According to an Oculis Pharma media release, Privosegtor is granted Breakthrough Therapy Designation by the USFDA supported by visual-function results from the Phase 2 ACUITY trial in optic neuritis (ON).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top